Welcome to our dedicated page for Perspective Therapeutics news (Ticker: CATX), a resource for investors and traders seeking the latest updates and insights on Perspective Therapeutics stock.
Perspective Therapeutics develops radiopharmaceutical candidates for cancer using proprietary Lead-212 (212Pb) technology and specialized targeting moieties. Its updates center on a theranostic approach that pairs targeted alpha therapy with complementary imaging diagnostics.
Recurring CATX news covers clinical and conference updates for VMT-α-NET in SSTR2-expressing neuroendocrine tumors, VMT01 for melanoma, and PSV359 for solid tumors, along with business results, financing activity, manufacturing infrastructure, 212Pb generator-enabled finishing facilities, and corporate presentations.
Perspective Therapeutics (CATX) announced a clinical trial collaboration and supply agreement with Merck (MRK)/b) on September 14, 2026 to evaluate Perspective’s targeted alpha therapy
The combination will be tested via an amendment to Perspective’s ongoing Phase 1/2a, multi-center, open-label, dose-finding and dose-expansion study (NCT06710756) in patients with certain non-small cell lung and colorectal cancers expressing FAP-α. The study has completed enrollment in the first three monotherapy dose cohorts. Perspective sponsors the trial, while Merck supplies pembrolizumab at no cost. PSV359 is designed to deliver the alpha-emitting isotope 212Pb to FAP-α–expressing tumors, with related imaging agents (203Pb/68Ga, PSV377) used to select patients and assess FAP-α expression.
Perspective Therapeutics (CATX) reports that updated data from its [212Pb]VMT-α-NET program have been accepted for presentation at the 38th EORTC-NCI-AACR Symposium 2026 in Barcelona.
The poster, led by Vikas Prasad of Washington University School of Medicine, will show cohort-level safety and efficacy results for [212Pb]VMT-α-NET in advanced SSTR2-positive neuroendocrine tumors (NETs), covering Cohorts 1–3, as Abstract 334 in the “New drugs” poster session on November 20, 2026.
[212Pb]VMT-α-NET is being evaluated in a multi-center, open-label, dose-escalation and dose-expansion trial (NCT05636618) in unresectable or metastatic SSTR2-positive tumors without prior radiopharmaceutical therapy, with additional data submissions planned for 2026 and 2027.
Perspective Therapeutics (NYSE American: CATX) reported 2Q 2026 results and pipeline progress, led by bamzireotide navoxetan (VMT-α-NET) in SSTR2-positive neuroendocrine tumors, which is being advanced toward a Phase 3 study targeting site activation around year-end 2026, subject to regulatory feedback.
VMT-α-NET has treated 76 NETs patients plus one meningioma patient, with ASCO 2026 interim data showing continued deepening of response and an ESMO 2026 oral update planned. The company also reported ongoing VMT01 melanoma and PSV359 solid tumor studies, pre-IND work on PSV594, manufacturing build-outs in Chicago and Los Angeles through 2027, cash and investments of about $237 million, and a 2Q 2026 net loss of $26.8 million, or $0.22 per share.
Perspective Therapeutics (NYSE American: CATX) will report its second quarter 2026 financial results and provide a business update on Monday, August 10, 2026, after the market closes. The earnings press release will be posted in the newsroom section of the company’s website.
Perspective Therapeutics is a radiopharmaceutical development company focused on cancer treatments using proprietary technology based on the alpha-generating isotope 212Pb. The company is advancing U.S. clinical-stage programs including VMT-α-NET (neuroendocrine tumors), VMT01 (melanoma), and PSV359 (solid tumors), and is expanding its finished drug product supply network enabled by its 224Ra/212Pb generator platform.
Perspective Therapeutics (NYSE American: CATX) announced that the European Commission has granted orphan medicinal product designation for [212Pb]VMT-α-NET for treating gastroenteropancreatic neuroendocrine tumors (GEP-NETs), following a positive opinion from EMA’s Committee for Orphan Medicinal Products.
According to the company, this designation may provide protocol assistance, fee reductions and, if [212Pb]VMT-α-NET is approved, up to 10 years of market exclusivity in Europe. The candidate is being evaluated in an ongoing multi-center, open-label Phase 1/2a study (NCT05636618) in patients with unresectable or metastatic SSTR2-positive tumors, with interim clinical data presented at ASCO 2026 and further data submissions planned in 2026–2027.
Perspective Therapeutics (NYSE American: CATX) announced that updated data from its radiopharmaceutical candidate [212Pb]VMT-α-NET have been accepted for an oral presentation at the ESMO Congress 2026, held October 23–27, 2026, in Madrid, Spain.
The rapid oral presentation, led by Thorvardur Halfdanarson of Mayo Clinic Comprehensive Cancer Center, will cover cohort-level safety and efficacy results for Cohorts 1–3 in advanced SSTR2-positive neuroendocrine tumors. The abstract (Number 2396RO) is scheduled for October 23, 2026, from 4:25–4:30 p.m. CEST. Perspective is running a multi-center, open-label, dose-escalation and dose-expansion trial (NCT05636618) in unresectable or metastatic SSTR2-positive tumors and previously shared interim data at ASCO 2026, with additional data submissions planned through 2027.
Perspective Therapeutics (NYSE American: CATX) appointed Paul Lyne, Ph.D. as Chief Science Officer, effective July 8, 2026. Co-founder and longtime CSO Michael K. Schultz, Ph.D. transitions to Senior Scientific Advisor & Co-Founder as part of a planned move toward retirement.
Lyne brings 25+ years of biopharma experience, including leadership of oncology research at Merck KGaA and contributions to 30+ oncology programs and multiple approved cancer drugs.
Perspective Therapeutics (NYSE AMERICAN: CATX) dosed the first meningioma patient with [212Pb]VMT-α-NET in an ongoing Phase 1/2a trial. This new LEMONαDE cohort will assess safety, dosimetry, and preliminary anti-tumor activity in SSTR2-expressing meningiomas, expanding development beyond neuroendocrine tumors and targeting a tumor type with limited treatment options.
Perspective Therapeutics (NYSE American: CATX) will present updated data from all three clinical programs at the 2026 ASCO Annual Meeting. Programs include [212Pb]VMT-α-NET for neuroendocrine tumors, [212Pb]VMT01 for melanoma, and [212Pb]PSV359 for FAP-expressing solid tumors.
Highlights feature two confirmed responses out of seven patients (29%) in the 3.0 mCi [212Pb]VMT01 melanoma cohort, generally well-tolerated safety profiles without dose-limiting toxicities, and continued deepening of responses for [212Pb]VMT-α-NET with additional follow-up.
Perspective Therapeutics (NYSE American: CATX) reported first patients dosed in new cohorts of two ongoing Phase 1/2a trials.
The fourth cohort of [212Pb]VMT-α-NET in SSTR2+ neuroendocrine tumors tests a front‑loaded 20 mCi regimen. A third cohort of [212Pb]PSV359 in FAP-α–expressing solid tumors opened after safety review of Cohort 2, with up to four 6.0 mCi doses every eight weeks.